López-Velázquez JA, Castro-Torres IG, Sánchez-Valle V, Méndez-Sánchez N

Language: English
References: 15
Page: 152-154
PDF size: 60.83 Kb.

Text Extraction

Original abstract
Background & aims. Cholestasis is a liver disorder characterized by impaired bile flow, reduction of bile acids (BA) in the intestine, and retention of BAs in the liver. The farnesoid X receptor (FXR) is the transcriptional regulator of BA homeostasis. Activation of FXR by BAs reduces circulating BA levels in a feedback mechanism, repressing hepatic cholesterol 7a-hydroxylase, the rate-limiting enzyme for the conversion of cholesterol to BA.

REFERENCES

1. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998; 339: 1217-27.

2. Méndez-Sánchez N, Chavez-Tapia NC, Uribe M. New molecular features of cholestatic diseases of the liver. Rev Invest Clin 2003; 55: 546-56.

3. Jung D, Podvinec M, Meyer UA, Mangelsdorf DJ, Fried M, Meier PJ, et al. Human organic anion transporting polypeptide 8 promoter is transactivated by the farnesoid X receptor/bile acid receptor. Gastroenterology 2002; 122: 1954-66.

4. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001; 120: 525-33.

5. Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, Suchy FJ. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 2001; 276: 28857-65.

6. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000; 6: 517-26.

7. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 2000; 6: 507-15.

8. Fiorucci S, Rizzo G, Donini A, Distrutti E, Santucci L. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol Med 2007; 13: 298-309.

9. Modica S, Moschetta A. Nuclear bile acid receptor FXR as pharmacological target: are we there yet? FEBS Lett 2006; 580: 5492-9.

10. Lee FY, Lee H, Hubbert ML, Edwards PA, Zhang Y. FXR, a multipurpose nuclear receptor. Trends Biochem Sci 2006; 31: 572-80.

11. Cariou B, Staels B. FXR: a promising target for the metabolic syndrome? Trends Pharmacol Sci 2007; 28: 236-43.

12. Zhang Y, Edwards PA. FXR signaling in metabolic disease. FEBS Lett 2008; 582: 10-8.

13. Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003; 17: 1581-91.

14. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, Mc- Donald JG, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 217-25.

15. Hofmann AF. Biliary secretion and excretion in health and disease: current concepts. Ann Hepatol 2007; 6: 15-27.